You just read:

FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations

News provided by

Tibotec Therapeutics

Dec 13, 2010, 06:37 ET